Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katz, S. L.
Right arrow Articles by Coates, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katz, S. L.
Right arrow Articles by Coates, A. L.
(Chest. 2001;119:250-255.)
© 2001 American College of Chest Physicians

Nebulizer Choice for Inhaled Colistin Treatment in Cystic Fibrosis*

Sherri L. Katz, MDCM; Sharon L. Ho, BSc, RRT and Allan L. Coates, MDCM, BEng (Elect)

* From the Division of Respiratory Medicine, Hospital for Sick Children, University of Toronto, Toronto, Canada.

Correspondence to: Allan Coates, MDCM, Division of Respiratory Medicine, Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8; e-mail: allan.coates{at}sickkids.on.ca

Study objectives: To develop practical ways of nebulizing colistin by determining the rate of drug output, total drug output, and particle-size distribution of two commercially available jet nebulizers, the disposable Hudson 1730 Updraft II (Hudson Respiratory Care; Temecula, CA) and the reusable Pari LC Star breath-enhanced nebulizer (Pari Respiratory Equipment; Midlothian, VA) .

Methods: The nebulizers contained colistin, 75 mg, in 4 mL of isotonic solution. Particle-size distribution was measured by helium-neon laser diffraction, allowing calculation of the respirable fraction (RF), the mass of aerosol comprised of droplets < 5 µm.

Results: The mean (95% confidence interval [CI]) total rate of output of the Updraft II was 2.6 mg/min (2.0, 3.1; n = 4) with 1.3 mg/min (1.0, 1.5) mg/min within the RF. The rate of output of the LC Star increased in a quadratic relationship to the inspiratory flow, delivering 1.8 mg/min (0.7, 2.0; n = 4) with 1.4 mg/min (1.3, 1.6) within the RF, and 6.2 mg/min (5.6, 6.8) with 5.3 mg/min (4.8, 5.7) within the RF, at 0 L/min and 20 L/min inspiratory flows, respectively. Efficiency, as the rate of expected pulmonary deposition divided by rate of total output, was then calculated. The LC Star estimated 56% (51, 61) efficiency, with pulmonary delivery of 29% (26, 32) of the charge of the nebulizer, compared to the Updraft II at 22% (22, 23) efficiency and expected pulmonary deposition of 10% (10, 10) of the dose.

Conclusions: Colistin can be successfully nebulized with both nebulizers tested. This study provides an estimate of in vivo efficiency and expected pulmonary deposition that may be used in future trials.

Key Words: cystic fibrosis • inhaled antibiotics • nebulizing colistin • Pseudomonas aeruginosa




This article has been cited by other articles:


Home page
 ChestHome page
G. A. Alothman, B. Ho, M. M. Alsaadi, S. L. Ho, L. O'Drowsky, E. Louca, and A. L. Coates
Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis
Chest, February 1, 2005; 127(2): 522 - 529.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. Jain and L. H Danziger
Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians
Ann. Pharmacother., September 1, 2004; 38(9): 1449 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Griese, J. Ramakers, A. Krasselt, V. Starosta, S. van Koningsbruggen, R. Fischer, F. Ratjen, B. Mullinger, R. M. Huber, K. Maier, et al.
Improvement of Alveolar Glutathione and Lung Function but Not Oxidative State in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., April 1, 2004; 169(7): 822 - 828.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. A. Alothman, M. M. Alsaadi, B. L. Ho, S. L. Ho, A. Dupuis, M. Corey, and A. L. Coates
Evaluation of Bronchial Constriction in Children With Cystic Fibrosis After Inhaling Two Different Preparations of Tobramycin*
Chest, September 1, 2002; 122(3): 930 - 934.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Chest Physicians.